JP5744213B2 - 赤血球減少に関連する疾病の予防又は治療用薬物の製造におけるアルクチゲニンの用途 - Google Patents

赤血球減少に関連する疾病の予防又は治療用薬物の製造におけるアルクチゲニンの用途 Download PDF

Info

Publication number
JP5744213B2
JP5744213B2 JP2013532041A JP2013532041A JP5744213B2 JP 5744213 B2 JP5744213 B2 JP 5744213B2 JP 2013532041 A JP2013532041 A JP 2013532041A JP 2013532041 A JP2013532041 A JP 2013532041A JP 5744213 B2 JP5744213 B2 JP 5744213B2
Authority
JP
Japan
Prior art keywords
arctigenin
group
myelosuppression
archigenin
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013532041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542205A5 (enExample
JP2013542205A (ja
Inventor
ツァオ，ツィクアン
Original Assignee
ルナン ファーマシューティカル グループ コーポレーション
ルナン ファーマシューティカル グループ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルナン ファーマシューティカル グループ コーポレーション, ルナン ファーマシューティカル グループ コーポレーション filed Critical ルナン ファーマシューティカル グループ コーポレーション
Publication of JP2013542205A publication Critical patent/JP2013542205A/ja
Publication of JP2013542205A5 publication Critical patent/JP2013542205A5/ja
Application granted granted Critical
Publication of JP5744213B2 publication Critical patent/JP5744213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013532041A 2010-10-08 2011-10-08 赤血球減少に関連する疾病の予防又は治療用薬物の製造におけるアルクチゲニンの用途 Active JP5744213B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010299279.X 2010-10-08
CN201010299279.XA CN102440986B (zh) 2010-10-08 2010-10-08 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途
PCT/CN2011/080543 WO2012045282A1 (zh) 2010-10-08 2011-10-08 牛蒡子苷元在制备预防或治疗血细胞减少相关疾病的药物中的用途

Publications (3)

Publication Number Publication Date
JP2013542205A JP2013542205A (ja) 2013-11-21
JP2013542205A5 JP2013542205A5 (enExample) 2014-01-09
JP5744213B2 true JP5744213B2 (ja) 2015-07-08

Family

ID=45927226

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013532041A Active JP5744213B2 (ja) 2010-10-08 2011-10-08 赤血球減少に関連する疾病の予防又は治療用薬物の製造におけるアルクチゲニンの用途

Country Status (7)

Country Link
US (1) US20130190394A1 (enExample)
EP (1) EP2626071B1 (enExample)
JP (1) JP5744213B2 (enExample)
KR (1) KR101512495B1 (enExample)
CN (2) CN102440986B (enExample)
AU (1) AU2011313667B2 (enExample)
WO (1) WO2012045282A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397547B (zh) * 2010-09-19 2013-06-12 山东新时代药业有限公司 一种抗癌药物组合物
CN102440986B (zh) * 2010-10-08 2014-12-03 鲁南制药集团股份有限公司 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途
CN103027906B (zh) * 2011-10-08 2015-11-11 鲁南制药集团股份有限公司 牛蒡子苷元在治疗贫血疾病中的应用
JP5707534B2 (ja) * 2012-03-26 2015-04-30 クラシエ製薬株式会社 抗癌剤
CN103446100A (zh) * 2012-05-29 2013-12-18 鲁南制药集团股份有限公司 牛蒡子苷元的舌下含服制剂
JP5696191B2 (ja) * 2013-04-27 2015-04-08 クラシエ製薬株式会社 抗癌幹細胞剤
CN104546823B (zh) * 2013-10-21 2019-08-30 鲁南制药集团股份有限公司 淫羊藿苷元在制备治疗或预防血小板减少症药物中的用途
JP6294476B2 (ja) * 2013-10-21 2018-03-14 ▲魯▼南制▲薬▼集▲団▼股▲フン▼有限公司 血球減少を予防又は治療するための薬物の製造におけるアンヒドロイカリチンの使用
US9907852B2 (en) 2014-04-10 2018-03-06 National University Corporation University Of Toyama Anticancer agent and side-effect-alleviating agent
JP6197077B1 (ja) * 2016-07-14 2017-09-13 クラシエ製薬株式会社 抗癌剤、放射線増感剤および食品組成物
CN110623960B (zh) * 2018-06-22 2022-08-19 成都山权江生物科技有限公司 一种小分子化合物在制备治疗阿尔茨海默病的药物中的应用
JP7675547B2 (ja) * 2021-04-01 2025-05-13 クラシエ株式会社 酸化ｌｄｌ増加抑制剤および酸化ｌｄｌ増加抑制用食品組成物
CN119462619B (zh) * 2024-11-06 2025-10-24 浙江大学 一种橙酮类化合物及其医药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CN1243103C (zh) * 2004-02-26 2006-02-22 广州中医药大学 一种制备抗病毒与抗肿瘤天然药物牛蒡子苷元的方法
JP2009523805A (ja) * 2006-01-17 2009-06-25 シグナル ファーマシューティカルズ，エルエルシー ＴＮＦα、ＰＤＥ４及びＢ−ＲＡＦの阻害剤、それらの組成物及びそれらの使用法
CN101036643A (zh) * 2006-03-13 2007-09-19 海南盛科天然药物研究院有限公司 含牛蒡子苷元的药物组合物及其制备方法
CN101134031B (zh) 2006-08-30 2012-05-09 山东绿叶天然药物研究开发有限公司 牛蒡子苷元在制备治疗或预防慢性肾功能衰竭及肾纤维化的药物中的用途
CN102210653B (zh) * 2010-04-03 2014-06-04 鲁南制药集团股份有限公司 牛蒡苷元的微乳制剂
CN102440986B (zh) * 2010-10-08 2014-12-03 鲁南制药集团股份有限公司 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途

Also Published As

Publication number Publication date
CN103209693A (zh) 2013-07-17
AU2011313667A1 (en) 2013-05-02
WO2012045282A1 (zh) 2012-04-12
US20130190394A1 (en) 2013-07-25
EP2626071B1 (en) 2016-01-13
JP2013542205A (ja) 2013-11-21
KR101512495B1 (ko) 2015-04-15
CN102440986B (zh) 2014-12-03
EP2626071A1 (en) 2013-08-14
HK1188122A1 (en) 2014-04-25
CN102440986A (zh) 2012-05-09
CN103209693B (zh) 2015-10-07
KR20130093125A (ko) 2013-08-21
AU2011313667B2 (en) 2015-08-27
EP2626071A4 (en) 2014-04-02

Similar Documents

Publication Publication Date Title
JP5744213B2 (ja) 赤血球減少に関連する疾病の予防又は治療用薬物の製造におけるアルクチゲニンの用途
US10799521B2 (en) Use of icaritin in preparing medicament for preventing or treating hematocytopenia
JP2016534074A5 (enExample)
CN102302737B (zh) 一种治疗胃癌的中药组合物
KR20130062329A (ko) 알로에 베라의 항바이러스 특성 및 후천성 면역 결핍 증후군(ａｉｄｓ) 치료
WO2012034540A1 (zh) 抗肿瘤药物组合物
CN104667197B (zh) 一种增强免疫力的组合物及其制备方法和应用
CN117205319B (zh) Hc030031在制备预防或治疗百草枯中毒引起的肺损伤的药物中的应用
CN104688722A (zh) 淫羊藿苷元在制备预防或治疗骨髓抑制药物中的用途
CN100427103C (zh) 一种海洋生物活性组合物及其用途
CN104771518B (zh) 一种抗炎、治疗或辅助治疗猪发热病的药物组合物及其制备方法
CN103027906A (zh) 牛蒡子苷元在治疗贫血疾病中的应用
CN109662968A (zh) 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
CN112807292A (zh) 白首乌二苯酮在制备降尿酸药物中的应用
EP3079709A1 (en) Ephedra alata extracts and methods of use thereof
CN110063988A (zh) 一种治疗神经母细胞瘤的药物组合物及其制备方法
CN113425723B (zh) Pim1小分子抑制剂在制备防治强直性脊柱炎产品中的应用
HK1188122B (en) Arctigenin for use in preventing or treating bone marrow suppression
CN107789343A (zh) 一种治疗偏头痛的药物及其制备方法
CN119950648A (zh) 一种治疗更年期抑郁症的中药组合物
CN118976012A (zh) 一种gsdmd抑制剂预防化疗时外周神经损伤的用途
CN114010657A (zh) 卵巢癌细胞在制备治疗胰腺癌药物中的应用
CN118615340A (zh) 芹槐提取物用于预防或治疗肝病的用途
CN110075302A (zh) 一种治疗抑郁和失眠的组合物及其用途
WO2006045238A1 (fr) Pollen carbonisé et son emploi dans la synthèse de médicaments anticancéreux

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141001

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150428

R150 Certificate of patent or registration of utility model

Ref document number: 5744213

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250